1. POMALIDOMIDE APPROVED FOR CML (EVEN T315I POSITIVE), A.L.L. PHILADELPHIA POSITIVE
2.T-DM 1 FOR HER-2 POSITIVE BREAST CANCERS.
3.APF530 FOR ACUTE AND DELAYED CHEMOTHERAPY INDUCED VOMITING
4 LYMPHOSEEK, TECHNETIUM, WILL SEEK SENTINEL NODES
5. CHEMOSAT FOR OCULAR MELANOMA METASTATIC TP THE LIVER, MELPHALAN BASED
6. TIVOZANIB ANTI-VEGF FOR METASTATIC RENAL CANCERS
7 AFATINIB FOR ADVANCED LUNG CANCER EGFR, ERB4 INHIBITOR
8. DABRAFENIB ANTI-BRAF IN MELANOMA
9. TRAMETINIB -ANTI MEK FOR ADVANCED MELANOMA
10 RADIUM-223 DICHLORIDE ALPHA PARTICLE EMISSION, IN BONE METASTASIS IN PROSTATE CANCER
A blog about research, awareness, prevention, treatment and survivorship of Breast Cancer and all cancers, including targeted scientific research and a grassroots approach to increase screening for cancer, especially in the low income and under-insured population of El Paso, Texas, with a view to expand this new health care model to many other 'minority' populations across the United States and beyond
Showing posts with label melphalan based. Show all posts
Showing posts with label melphalan based. Show all posts
Saturday, February 16, 2013
DRUGS IN THE PIPELINE PER "ONCOLOGY LIVE"
Labels:
ALL,
anti-vegf,
APF530,
chemosat,
chemotherapy induced vomiting,
cml,
crbcm,
lymphoseek,
melphalan based,
new cancer drugs,
ocular melanoma,
philadelphia positive,
pomalidomide,
sentinel noes,
technetium,
Tivozanib
Subscribe to:
Posts (Atom)